[The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome].

Atypical hemolytic-uremic syndrome (aHUS) is a chronic systemic disease of a genetic nature, which is based on uncontrolled activation of the alternative complement pathway, leading to generalized thrombosis in the vessels of the microvasculature (complement-mediated thrombotic microangiopathy). To date, therapy with eculizumab is the most effective and pathogenetically substantiated method of treating patients with ASH. Using the example of three clinical cases of patients with a verified diagnosis of aHUS, the high efficiency and safety of the worlds first bioanalogue of eculizumab in the treatment of adult patients with aHUS (complement-mediated thrombotic microangiopathy) was demonstrated.

[THE MECHANISMS OF ACTION OF RITUXIMAB].

Rituximab is a chimeric monoclonal antibody containing constant kappa-regions of the Fc fragment of IgGI human immunoglobulin and variable fragments of IgG murine immunoglobulin. This modified immunoglobulin structure makes rituximab capable of specifically recognizing CD20 antigen that is mainly expressed on B-lymphocytes. The review considers four main mechanisms of rituximab action leading to reduction of the population of B-lymphocytes in patients with lymphoproliferative processes.

Changes in the colicinogenic and hemolytic activities of Escherichia isolated from man during long-term confinement.

The paper presents data obtained during the year-long medico-engineering experiment (in which three test subjects participated) with respect to changes in the Escherichia composition as judged by colicinogenic and hemolytic activity. At the beginning of the experiment colicinogenic E. coli (col/D and col/B) was found in one of the three test subjects (U-85%); he also showed the highest stability of intestinal microflora throughout the experiment.